What are the key insights from James Hicks's interview with BioRestorative CEO Lalstodt?

Hi there! I recently sat down 1:1 with Lance Alstodt, President, CEO and Chairman of BioRestorative Therapies, a company focused on regenerative biology and stem cell therapies for highly prevalent conditions.

Based on that conversation, here are the big takeaways:

• BioRestorative is moving from early development into more advanced clinical trials, funded in part by its uplist from OTC to Nasdaq
• The core mission is to address unmet patient needs with stem cell–based treatments, not just incremental therapies
• There’s active work on educating the public and countering skepticism around stem cells with data and transparent studies
• The team is focused on what they’re doing for patients today and how to follow their clinical studies and upcoming milestones

Would you like a short, patient-focused summary or a more investor-focused one?